Biotech

Why Biologics Manufacturing Demands Tighter Control

Vaccines and other biologics are grown in living cell cultures rather than synthesized chemically, which makes contamination control the central engineering challenge. A single microbial intrusion into a client's bioreactor batch can destroy weeks of cultivation, so biologics facilities are held to some of the strictest cleanroom standards in manufacturing — typically ISO 5 (equivalent to Grade A) for the critical processing zone, with an ISO 6-7 background.

Sterile Filling Systems and Infrastructure Around the Bioreactor

Bioreactors used for vaccine and biologic production range from bench-scale vessels to large 50–2,000+ litre systems. The client operates the cell culturing and fermentation process itself; ARGOTEX is responsible for the infrastructure around it — CIP/SIP (clean-in-place / sterilize-in-place) piping loops, sterile fill-finish systems, and the cleanroom environment, all under the same HVAC and pressure cascade discipline as the fill-finish area.

Regulatory Oversight

Biologics facilities are typically reviewed against FDA, EMA, and WHO GMP guidance in addition to local requirements, with particular attention to environmental monitoring programs, HEPA/ULPA filtration (removing ≥99.97% of particles ≥0.3 µm), and aseptic fill-finish isolator systems for the final sterile product.

How ARGOTEX Supports Biotech Facilities

ARGOTEX designs sterile fill-finish isolators and CIP/SIP piping networks around the client's bioreactor systems, delivered inside fully validated cleanroom environments — engineered to the ISO 14644 and PIC/S GMP standards biologics regulators expect.